An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings. Journal of Visualized Experiments (JoVE), (85): e51242, doi:10.3791/51242 (2014).

Publication Latest Publications

Title: An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Authors: Manasa J, Danaviah S, Pillay S, Padayachee P, Mthiyane H, Seebregts C, Rinke De Wit TF, Viljoen J, Katzenstein D, De Oliveira T .
Journal: Journal of Visualized Experiments (JoVE),(85):e51242, doi:10.3791/51242 (2014)

Journal Impact Factor (I.F.): 1.2
Number of citations (Google Scholar): 11

Abstract

HIV-1 drug resistance has the potential to seriously compromise the effectiveness and impact of antiretroviral therapy (ART). As ART programs in sub-Saharan Africa continue to expand, individuals on ART should be closely monitored for the emergence of drug resistance. Surveillance of transmitted drug resistance to track transmission of viral strains already resistant to ART is also critical.

Unfortunately, drug resistance testing is still not readily accessible in resource limited settings, because genotyping is expensive and requires sophisticated laboratory and data management infrastructure. An open access genotypic drug resistance monitoring method to manage individuals and assess transmitted drug resistance is described.

The method uses free open source software for the interpretation of drug resistance patterns and the generation of individual patient reports. The genotyping protocol has an amplification rate of greater than 95% for plasma samples with a viral load >1,000 HIV-1 RNA copies/ml. The sensitivity decreases significantly for viral loads <1,000 HIV-1 RNA copies/ml. The method described here was validated against a method of HIV-1 drug resistance testing approved by the United States Food and Drug Administration (FDA), the Viroseq genotyping method.

Limitations of the method described here include the fact that it is not automated and that it also failed to amplify the circulating recombinant form CRF02_AG from a validation panel of samples, although it amplified subtypes A and B from the same panel.

The video component of this article can be found at http://www.jove.com/video/51242/

Download: Full text paper

Citation: Manasa J, Danaviah S, Pillay S, Padayachee P, Mthiyane H, Seebregts C, Rinke De Wit TF, Viljoen J, Katzenstein D, De Oliveira T . An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings Journal of Visualized Experiments (JoVE),(85):e51242, doi:10.3791/51242 (2014).

Video/Movie


View: Video at YouTube

SATuRN/Life Technologies open access and affordable drug resistance genotyping system. This is a video that accompain a peer-reviewed manuscript that provides detailed information on how to our affordable drug resistance testing. The paper and video are open accessible!


For more videos please visit BioAfrica & SATuRN YouTube Channel


Impact of point-of-care Xpert MTB/RIF on tuberculosis treatment initiation: a cluster randomised trial
Journal: Am J Respir Crit Care Med (2017)

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
Journal: Pharmacogenomics and Personalized Medicine (2017)

Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa
Journal: Journal of Antimicrobial Chemotherapy (2017)
All publications...


KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN

Contact: Prof. Tulio de Oliveira, Tel: +27 31 260 4898, Email: tuliodna@gmail.com & deoliveira@ukzn.ac.za

Page design updated 2013. Many of the pages were previously hosted at bioafrica.net.